Generic Sterile Injectables Market, by Drug Type (Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines, Immunoglobulins, Blood Factors, Antibiotics, and Others), by Therapeutic Application (Cancer, Metabolic Diseases, Cardiovascular Diseases, Central Nervous System Disease, Infectious Disorders, Musculoskeletal Disorders, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Mar 2024

Code : CMI519

Pages :387

Formats :

Excel and PDF

Industry : Pharmaceutical

Leading Companies

Market players are engaged in receiving approvals from the regulatory authorities, in order to expand their product portfolio. This is expected to drive growth of the global generic sterile injectables market over the forecast period.

Key players are focused on receiving approvals from the regulatory authorities and this is expected to drive growth of the global generic sterile injectables market over the forecast period. For instance, in 2022, Sandoz, a unit of Novartis AG, announced the approval from the U.S. Food and Drug Administration (FDA) for the generic version of Copaxone which is indicated for the treatment of patients with relapsing forms of multiple sclerosis.

Moreover, for instance, in 2019, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved ZIRABEV (bevacizumab-bvzr), a biosimilars to Avastin (bevacizumab), 1 for the treatment of five types of cancer: metastatic colorectal cancer; unrespectable locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC); recurrent glioblastoma; metastatic renal cell carcinoma (RCC); and persistent, recurrent or metastatic cervical cancer.

Increasing inorganic activities such as acquisitions, in order to increase the product portfolio is expected to drive the growth of the global generic sterile injectables market over the forecast period

Market players are focused on inorganic activities such as acquisitions and is expected to drive growth of the global generic sterile injectables market over the forecast period. For instance, in March 2020, Baxter International Inc., expects sales to grow approximately 4% on a compounded annual basis at constant currency rates from 2016 to 2020 by focusing on cost optimization and portfolio management. The company is expected to generate free cash flow of approximately US$ 1.75 Bn in 2020.

Moreover, in 2017, Fresenius Kabi AG, healthcare company, acquired Akorn, Inc., manufacturer of over the- counter pharmaceuticals products, for approximately US$ 4.3 billion. This acquisition represents a potential innovative growth opportunity for its sterile injectables business portfolio.

Global Generic Sterile Injectables Market – Competitive Landscape

Major players operating in the global generic sterile injectables market include Baxter International Inc., AstraZeneca plc, Merck & Co., Inc., Pfizer Inc., Fresenius Kabi, Novartis International AG, Teva Pharmaceuticals, Hikma Pharmaceuticals, Dr. Reddy’s Laboratory, Mylan N.V. and Sun Pharmaceutical Industries Ltd.